Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 7Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Stromal Tumors 3Central Nervous System Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms by Site 2Melanoma 2Medulloblastoma 2Lung Neoplasms 2Lung Diseases 2Glioma 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Thyroid Carcinoma, Anaplastic × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡